Avantogen Oncology, Inc., a biotechnology company, engages in the acquisition and development of compounds to treat various types of cancer. Its products include INOC-001, a chemo-resistance inhibitor, which is in extended Phase I/II trials in Germany. The company also conducts Phase III and final Phase I study for INOC-001 to test dose-escalation in patients with metastatic pancreatic cancer. In addition, it develops INOC-005, which is a preclinical efficacy testing completed chemical entity that would be used for the treatment of prostate cancer; and INOC-009, a preclinical testing completed product, which is a reformulation of an intravenous chemotherapeutic agent that treats various types of cancer, including breast, ovarian, and AIDS-related Kaposi's sarcoma. The company has a joint venture partnership in Resistys, Inc. to develop INOC-001; and an agreement with Prostagenics, LLC to develop and commercialize INOC-005. Avantogen Oncology was founded in 1986. It was formerly known as Innovate Oncology, Inc. and changed its name to Avantogen Oncology, Inc. in July 2006. The company is headquartered in Los Angeles, California. Avantogen Oncology, Inc. is a subsidiary of Avantogen Limited.
Gallery View 4: (Full Sto, MACD, Aroon8)